Precigen Inc
PGEN
NASDAQ
Biotechnology
$6.10
USD
-0.39 (-6.01%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.33B
Volume 7.9M
Revenue
$85.72M
TTM
+1875.0%
YoY
Gross Margin
91%
TTM
+13217.3%
YoY
Net Income
$-157.71M
TTM
-26.7%
YoY
Operating Cash Flow
$-114.17M
TTM
-72.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.9 | 2.9 | 4.6 | 23.3 | 55.0 |
YoY Growth | +19.4% | +206.6% | +283.6% | +1633.9% | +6322.7% |
Cost of Revenue | 1.1 | 1.0 | 1.6 | 2.6 | 2.8 |
Gross Profit | -0.2 | 1.9 | 3.0 | 20.7 | 52.2 |
Selling, General & Administrative | 16.1 | 24.0 | 17.6 | 21.0 | 22.2 |
Other Operating Expenses | 3.9 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 31.5 | 36.4 | 24.6 | 26.7 | 29.5 |
Operating Income | -31.8 | -34.5 | -21.7 | -6.0 | 22.6 |
EBITDA | -27.2 | -33.7 | -20.5 | -4.9 | 23.7 |
Other Income / Expense | 4.4 | -111.5 | 0.1 | 0.3 | 0.0 |
Total Other Income / Expense | 5.1 | -111.9 | -1.8 | -1.9 | -2.6 |
Income Before Income Taxes | -26.6 | -146.3 | -23.5 | -7.9 | 20.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -26.6 | -146.3 | -23.5 | -7.9 | 20.1 |
Consolidated Net Income / Loss | -26.6 | -146.3 | -23.5 | -7.9 | 20.1 |
Net Income Attributable to Common Shareholders | -26.6 | -325.3 | -23.5 | -7.9 | 20.1 |
Basic EPS | -$0.09 | -$1.06 | -$0.07 | -$0.02 | $0.06 |
Diluted EPS | -$0.09 | -$1.06 | -$0.07 | -$0.02 | $0.05 |
Basic Shares Outstanding | 296.4M | 307.2M | 354.4M | 354.3M | 356.9M |
Diluted Shares Outstanding | 296.4M | 307.2M | 354.4M | 354.3M | 413.7M |